Loading clinical trials...
Loading clinical trials...
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)
Conditions
Interventions
Maridebart cafraglutide
Placebo
Locations
596
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
SEC Clinical Research
Dothan, Alabama, United States
Eastern Shore Research Institute
Fairhope, Alabama, United States
Heart Center Research LLC
Huntsville, Alabama, United States
HonorHealth
Phoenix, Arizona, United States
Medical Advancement Centers of Arizona
Phoenix, Arizona, United States
Start Date
June 25, 2025
Primary Completion Date
June 30, 2028
Completion Date
September 29, 2030
Last Updated
April 24, 2026
NCT07351045
NCT07508241
NCT07244458
NCT07311850
NCT07395687
NCT05746039
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions